Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial.
Näslund U, Ng N, Lundgren A, Fhärm E, Grönlund C, Johansson H, Lindahl B, Lindahl B, Lindvall K, Nilsson SK, Nordin M, Nordin S, Nyman E, Rocklöv J, Vanoli D, Weinehall L, Wennberg P, Wester P, Norberg M; VIPVIZA trial group.
Näslund U, et al. Among authors: nyman e.
Lancet. 2019 Jan 12;393(10167):133-142. doi: 10.1016/S0140-6736(18)32818-6. Epub 2018 Dec 3.
Lancet. 2019.
PMID: 30522919
Clinical Trial.